You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Survival by subgroup in ITT population

From: Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study

Subgroup Median OS (95%CI) months 1-year survival rate
% no./total no.
Overall 11.0 (6.9 – 19.8) 45.0 13/29
Gender    
Female 13.9 (6.9 – 19.8) 53.3 8/15
Male 8.7 (4.7 – 14.6) 36.4 5/14
Performance status    
ECOG 0 10.8 (6.9 – 19.8) 43.8 7/16
ECOG 1 11.0 (5.1 – 19.8) 46.8 6/13
Metastasis stage    
M1a 14.6 (10.3 – 14.6) 66.7 2/3
M1b 19.8 (1.2 – 19.8) 75.0 3/4
M1c 8.8 (6.3 – 14.3) 36.4 8/22
Age    
≤60 years 9.8 (6.4 – 14.6) 30.0 3/10
>60 years 13.9 (6.3 – 19.8) 53.1 10/19
Pre-treatment    
1 11.3 (6.9 - 13.9) 46.9 7/15
≥2 10.0 (5.1 – 14.6) 42.9 6/14
Patients    
Non-progressive 14.2 (11.3 – 19.8) 72.7 8/11
Progressive 8.4 (5.1 – 11.0) 28.1 5/18
  1. OS = overall survival, ITT = intention to treat, CI confidence interval.